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Abstract

There is a vital need to find new clinical treatment options to combat ESKAPE pathogen
infections. Nature has thus far been the most fruitful at providing antimicrobial
compounds, which have been derived from a plethora of sources. Ranging from plants to
microbial communities, these organisms create chemical compounds that are used as
defense mechanisms against invasive or encroaching organisms and confer the
producers with competitive advantages. In this study, cinnamaldehyde was investigated
as a botanical approach to finding active antimicrobial compounds that inhibit the
ESKAPE pathogens. Here, we show that all the ESKAPE pathogens are inhibited by
cinnamaldehyde concentrations between 105 µg/mL and 630 µg/mL. To test biofilm
eradication capabilities of cinnamaldehyde, we show that at the MIC, there is <50%
biofilm recovery for E. faecium, K. pneumoniae, A. baumannii, P. aeruginosa, and E.
cloacae. Adaptive mutation assays showed that A. baumannii and S. aureus did not gain
resistance to cinnamaldehyde after repeated exposure in comparison to known drug
controls. On a biological level, microbial means of inhibiting the ESKAPE pathogens by
use of secondary metabolite production was explored as well. In this study, bacteria were
isolated and characterized from marine sediment samples collected from the Gulf of
Mexico, Hawaii, and Antarctica, and their secondary metabolites tested for growth
inhibition against the ESKAPE pathogens. Of the 286 isolates tested, 22 had metabolites
inhibiting the growth of S. aureus, E. faecium or both, whilst an additional organism

v

produced metabolites that inhibited K. pneumoniae, E. cloacae as well as both Grampositive species. From a microbial ecology perspective, following DNA sequencing of the
16S-23S rRNA genes from our microbial collection, 102 were found to be Proteobacteria,
100 were Firmicutes, whilst 47 were from the phylum Actinobacteria. Surprisingly, four
were considered to-date uncultured, and therefore are a potential goldmine for novel
metabolites and potential future antibiotics. Collectively, compounds derived from
botanical and microbial sources can be harnessed for the discovery and development of
potential future antibiotics.

vi

Chapter 1: Antimicrobial Activity of Cinnamaldehyde against the ESKAPE
Pathogens
Introduction

Multi-Drug Resistant Bacteria
Nosocomial infections are on the rise in hospital settings due to increasing
rates of antibiotic resistance. Yet, this rise in antibiotic resistance is not shared equally
among all infectious bacteria, with the most difficult to treat hospital acquired infections
seemingly caused by six major pathogens (1). The Infectious Disease Society of America
(ISDA) coined the acronym “ESKAPE” denoting the six most drug resistant pathogens
responsible for 2/3 of US nosocomial infections (Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
and Enterobacter cloacae). Approximately 100,000 deaths are caused by these
nosocomial infections each year in the country (2). One reason why these pathogens are
such successful infectious agents is due to their biofilm formation abilities. The ESKAPEs
create and enclose themselves in extracellular matrix (ECM) resulting in protection from
antibiotics and the host immune system (3). Furthermore, many of the virulence factors
that they express are controlled by cell-density dependent communication. This type of
communication is required for biofilms to be formed, hence, creating infections (4). It is
estimated that 80% of all infections are due to bacterial biofilms in which treatment options
are essentially nonexistent (5).
1

Characteristics of the ESKAPE Pathogens
The main characterizing attributes of the ESKAPE pathogens are their
ability to escape drug inhibition through multiple mechanisms of resistance. Antibiotic
resistance is the cause of approximately 50,000 deaths per year in the US and Europe
(6). This number is expected to increase to ten million deaths by 2050 if there is no
antibiotic discovery breakthrough (6). Another disturbing feature of the ESKAPE
pathogens is that they are opportunistic in nature, with most strains seemingly able to
exist as harmless commensals in the human body. E. faecium, for example, is a Grampositive microorganism found commonly in the human gastrointestinal tract. It is normally
non-virulent in this locale, but, when the density of E. faecium colonization increases
unabated, infections can arise. If this bacterium crosses the intestinal lining and reaches
the bloodstream, infectious endocarditis can occur (7). S. aureus is the only other Grampositive bacterium within the ESKAPE set, and exists in a commensal state, colonizing
as many as one in every three people in the anterior nares. When it moves from this site
and enters the body through a cut or an infected prosthetic transplant it can cause myriad
potentially fatal infections. It can also serve as an intracellular pathogen and specifically
infects keratinocytes and leukocytes (8). K. pneumoniae is an opportunistic pathogen that
is a leading cause of urinary tract infections and can cause surgical site infections,
pneumonia and blood infections. Of specific concern, there is a high mortality rate (1640%) with patients suffering from K. pneumoniae bacteremia, particularly for those who
are immunocompromised (9). A. baumannii, or “Iraqibacter”, was a common pathogen
among soldiers that returned from Iraq with infected burn wounds to our hospitals (10).
This pathogen causes many infections including pneumonia, wound infections,
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bacteremia and meningitis (11). P. aeruginosa is the cause of 96% of deaths in cystic
fibrosis patients. This pathogen is effective due to its secreted acyl homoserine lactones
which aid in cell density dependent gene regulation of virulence factors (12). Finally, E.
cloacae is yet another GI-dwelling, opportunistic pathogen that causes urinary tract
infections, pneumonia and septicemia (13). This bacterium also has a high infection rate
of prosthetic implants (14). Together, these six pathogens cause a wide array of deadly
infections in which the number of possible treatment options are declining (15). The
ESKAPE pathogens have developed multiple mechanisms of resistance against drugs
including efflux pumps, drug target modification, biofilm formation, enzymatic inactivation
of antibiotics and more (15). This multitude of infections and our diminished ability to treat
the infections these organisms cause has become a worldwide threat.
Ethnobotanical Antibacterial Compounds
Plant products being used to treat illnesses and ailments is an ancient idea
(16). People from all continents have made medicinal use of plants dating back centuries.
Traditional Chinese Medicine (TCM) and Ayurvedic medicine from India are two of the
main approaches to medicine using herbs and natural products to treat diseases and
infections. The golden age of antibiotic discovery was from the 1950s to the 1960s, during
which half of the drugs used today were discovered (17) Since this time period, the use
of plant products as antimicrobial treatment options has hit an all-time low. Scientists
from biological and chemical disciplines have recognized the short life span of current
antibiotics and are scouring the earth in search for new antimicrobial treatment options
(18). One such source in this regard is presented by ethnobotanical antibacterial
compounds. Plant compounds can be extracted by various processes and solvents, but
3

mainly through steam distillation of the plant material. Approximately 119 compounds
originating from 91 plants form the active constituents of important drugs used today (19).
Plant products are highly successful at inhibiting microbes due to their production of an
array of secondary metabolites, including tannins, terpenoids, alkaloids and flavonoids
(18). The essential oils derived from different parts of plants contain these volatile,
odorous compounds that can be used for many medicinal purposes. Thyme essential oil,
for example, showed antimicrobial effects on multi-drug resistant E. coli strains (20).
Other oils like clove, myrrh, tea tree, have been used historically as antiseptics when used
topically (21). Another essential oil that has shown antibacterial activity across a vast
number of pathogens is cinnamon bark essential oil (22).
Medicinal Uses of Cinnamaldehyde
Cinnamon essential oil is derived from the cinnamon tree belonging to the
genus Cinnamomum. This plant is native to Sri Lanka but is also found in other parts of
Asia. Different parts of the plant, such as the roots, bark, leaves, and fruit are harvested
to collect chemically distinct essential oils (23). The main oil that is used for its
antimicrobial effects is cinnamon bark essential oil with the most active constituent being
cinnamaldehyde. Cinnamaldehyde is an aromatic aldehyde that, along with eugenol,
makes up cinnamon essential oil (24). This phytochemical has been shown to be affective
at inhibiting Salmonella typhimurium (25), Salmonella enteritiditis (26), Listeria
monocytogenes (27), Escherichia coli (28), and many other bacteria. Not only is
cinnamaldehyde used in antimicrobial studies but has also been shown to have
anticancer properties as well when tested against cancerous mouse models and against

4

human cancer cells (29). Until now, cinnamaldehyde has not been tested for antimicrobial
activity against a clinical library of ESKAPE pathogens.
The aim of this study is to illustrate the possibility of cinnamaldehyde being
a potential therapeutic agent for the plethora of infections caused by the ESKAPE
pathogens. To assess this, antimicrobial susceptibility assays were performed to discover
the minimum inhibitory-, bactericidal- and biofilm eradication- concentrations of
cinnamaldehyde against our clinical ESKAPE pathogen strains. This was followed by
checkerboard assays with commercial antibiotics to better elucidate the mechanism of
action for cinnamaldehyde in inhibiting bacterial pathogens. Also, synergistic activity has
the advantage of revealing the possible therapeutic use of cinnamaldehyde in adjunction
with antibiotics given at a lower dosage to decrease antibiotic resistance and adverse
side effects from the antibiotics. To ensure that bacteria do not gain resistance to
cinnamaldehyde, S. aureus and A. baumannii were used in an adaptive mutation assay
as well. Cinnamaldehyde was also tested for cytotoxicity against human kidney cells, and,
finally, in protein binding studies to determine mechanism of action against S. aureus.

Materials and Methods

Bacterial Strains and Antimicrobial Agent
Clinical isolates of the ESKAPE pathogens used in this study are
summarized in Table 1 and in (2). All assays were performed using bacterial cultures
grown in five milliliters of Tryptic Soy Broth (TSB) for 18 – 24 hours in a 37˚C shaking
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incubator. Cinnamaldehyde was purchased from Sigma Aldrich (W228613, natural,
≥95%) in an aqueous solution and diluted in dimethyl sulfoxide (DMSO).
Antimicrobial Susceptibility Assays
The broth microdilution method was used to determine the minimum
inhibitory concentration (MIC) of cinnamaldehyde against E. faecium, S. aureus, K.
pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae. Cinnamaldehyde was serial
diluted two-fold from 10.5 mg/mL to 0.082 mg/mL alongside a 0 mg/mL DMSO control
and tested in technical triplicate against all the ESKAPE pathogens; all of which were
diluted 1:1000 from overnight cultures in the appropriate media. Gram-positive bacteria
were tested in Tryptic Soy Broth (TSB) while Gram-negative bacteria were tested in
Mueller Hinton Broth II (MHBII). In each testing well, there were: 96 microliters of broth,
4 microliters of diluted cinnamaldehyde, and 100 microliters of diluted bacteria. The 96well plates were placed in the 37˚C shaking incubator for 18 – 24 hours and MICs were
determined by visually inspecting the wells for antimicrobial activity based on turbidity or
clearness of the media.
The minimum bactericidal concentration (MBC90) was determined to be the
concentration at which there was ≥90% eradication of the bacteria upon treatment with
cinnamaldehyde. To do this, the MIC assay was repeated, and, after incubation, 30 µL of
each triplicate well at 0X, 1X, and 4X the MIC were removed from that 96-well plate and
added to a fresh 96-well plate that contained 270 µL of PBS. The bacteria in these wells
were diluted ten-fold, seven times. From each of these, 30 µL of bacterial dilutions were
plated in duplicate on TSA plates and incubated at 37˚C for 18 – 24 hours. The colony
forming units (CFUs) were counted after the incubation period and statistically significant
6

quantities (30-300 CFUs) were recorded for data analysis. The CFU/mL was calculated
by dividing the number of CFUs counted by the volume of bacteria plated (0.03 mL) and
multiplying that by the dilution factor (10x). Percent recovery was calculated by dividing
the CFU/mL by the average of the no drug wells and multiplying by 100.
Minimum biofilm eradication concentration (MBEC90) was used to test for
viable bacterial cells from the ESKAPE pathogen biofilms after treatment with
cinnamaldehyde at 0X, 1X and 4X the MIC of each pathogen. The MBEC 90 was the
concentration at which ≥90% of the bacteria were eradicated. To accomplish this,
overnight cultures of the ESKAPE pathogens were diluted to an OD600 of 0.5 and 200 µL
were aliquoted in triplicate into 96-well plates. These were incubated for 18 – 24 hours at
37˚C in a static incubator. After incubation, 200 µL of the media was carefully removed
from the wells and 200 µL of fresh media (TSB) was added. The 200 µL of fresh media
was comprised of 196 µL of TSB, and 4 µL of cinnamaldehyde diluted to 0X, 1X and 4X
the MIC in DMSO. These 96-well plates were incubated again in a static, 37˚C incubator
for 18 – 24 hours. Biofilms were then carefully washed with PBS to remove
cinnamaldehyde. This was done by removing 150 µL media and adding 200 µL of PBS.
Next, 210 µL of PBS/media solution was removed, and 200 µL fresh PBS was added
back into the wells. All liquid in the wells were aspirated out and biofilms were disrupted
from the sides and bottom of the wells by adding 200 µL of PBS and rapidly pipetting up
and down. Finally, 30 µL of each well in triplicate was removed from the 96-well plate and
added to a fresh 96-well plate that contained 270 µL of PBS. Serial dilution and percent
recovery calculations were performed as described above.
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Synergistic Activity of Cinnamaldehyde and Antibiotics
In attempt to elucidate cinnamaldehyde’s mechanism of action as well as test its
synergistic effects with different antibiotics, checkerboard assays were used. For this
experiment, the following antibiotics were tested with cinnamaldehyde against A.
baumannii: Ciprofloxacin, Polymyxin B, Doxycycline, Rifampicin, Rifabutin, Triclosan, and
Rifamycin.

Rifabutin,

Tetracycline,

Vancomycin,

Gentamycin,

Daptomycin

and

Chloramphenicol were tested with cinnamaldehyde against S. aureus. To assess
synergistic effects, both treatments were tested starting at their MICs and serial diluted
seven times for the antibiotics, and eleven times for the cinnamaldehyde. In a 96-well
plate, 94 µL of broth was added to each well, then, along the y-axis of the wells (from
rows A-H) 2 µL of the antibiotic tested was added, starting with the MIC at the top row (A)
and each subsequent dilution following all the way down the plate seven times (rows AG), with the final row having 2 µL of vehicle only control. Cinnamaldehyde was added in
a similar fashion but instead of from the top of the plate to the bottom, 2 µL was added
from left to right in decreasing concentrations (from columns 1-12). The MIC was tested
in column 1, with each subsequent dilution added in the following column until reaching
column 12, which was treated with 2 µL of DMSO control. The MICs for the antibiotics
tested against S. aureus are: Tetracycline at 0.34 µg/mL, Rifabutin at 0.195 µg/mL,
Vancomycin at 6.25 µg/mL, Daptomycin at 25 µg/mL, Chloramphenicol at 50 µg/mL and
Gentamycin at 3.125 µg/mL. The MICs for the antibiotics tested against A. baumannii are:
Ciprofloxacin at 100 µg/mL, Doxycycline at 0.78 µg/mL, Polymyxin B at 1.56 µg/mL,
Rifampicin at 3 µg/mL, Rifabutin at 6.25 µg/mL, Triclosan at 0.78 µg/mL, and Rifamycin
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at 3.125 µg/mL. In order to calculate the FIC (fractional inhibitory concentration) index of
the

checkerboard

assay,

the

following

equation

was

used:

∑ 𝐹𝐼𝐶 = 𝐹𝐼𝐶 𝑎𝑔𝑒𝑛𝑡 𝐴 + 𝐹𝐼𝐶 𝑎𝑔𝑒𝑛𝑡 𝐵

FIC agent A is equivalent to dividing the MIC of treatment agent A (antibiotic) in
combination with cinnamaldehyde (treatment agent B) by treatment agent A alone.
Likewise, FIC agent B is equivalent to dividing the MIC of treatment agent B in
combination with treatment agent A by the MIC of treatment agent B alone.
Pathogen Adaptation to Cinnamaldehyde
To determine whether S. aureus and A. baumannii can adapt to
cinnamaldehyde treatment and therefore gain resistance to it, these two pathogens were
passaged against increasing concentrations of cinnamaldehyde alongside a drug control
for eight consecutive days. The S. aureus strain used for this assay was not our standard
635 isolate, but USA300 instead, since 635 already had resistance to most antibiotics
used in the laboratory (thus impacting our control testing). To begin, 96 µL of media was
aliquoted in triplicate into a 96-well plate. Sub-MIC concentrations were used to start this
experiment, thus: 4 µL of cinnamaldehyde diluted to 210 µg/mL for S. aureus and 105
µg/mL for A. baumannii was added to each well. Finally, 100 µL of bacteria diluted 1:100
(for this experiment exclusively) was added to each well. The OD600 was read on a plate
reader before placing the plates in the 37˚C shaking incubator for 18 – 24 hours and the
OD600 was read again after incubation. Each day this protocol was repeated with the only
changes being that the concentration of cinnamaldehyde was doubled in each well and
that the bacteria used each day was not from a fresh culture but rather from the wells of
9

the previously incubated plate. The antibiotic controls used for this experiment were
Vancomycin for S. aureus and Tetracycline for A. baumannii.
Cinnamaldehyde Cytotoxicity to Human Kidney Cells
To reveal whether cinnamaldehyde is toxic to human cells, cytotoxicity
assays were conducted using HEK (human embryonic kidney) 293 cells. To do this, HEK
293 cells were added to 10 mL of media (DMEM) and centrifuged at 1000 rpm for five
minutes. Supernatants were removed, and cells were re-suspended in 20 mL of media
and added to a T75 flask and incubated at 37˚C with 5% CO2 for 1-2 days. When cells
had 80% – 90% confluence, media was removed from the flask and cells were washed
three times with 5 mL cell culture PBS. After washing, 3 mL of trypsin EDTA was added
to detach cells from the bottom of the flask. Cells were immediately washed with 3 mL of
media three times and be diluted 1:4 in fresh media. A Neubauer chamber (C-Chip) was
used to count cells under the microscope by adding 20 µL of cell culture to the chip. The
final dilution of cells was 5,000 cells in 100 µL which was the final volume added to each
test well of a 96-well plate. These cells were incubated for 24 hours at 37˚C with 5% CO2
to allow cells to attach and replicate. After incubation, 100 µL was carefully removed and
196 µL of media was added back into the wells along with 4 µL of cinnamaldehyde
treatment diluted in 75% DMSO solution (3:1 DMSO to water); alongside vehicle only
controls. Treatment wells and control wells were assayed in triplicate starting at 420
µg/mL and serial diluted eight times. The 96-well plate was incubated for 48 hours at 37˚C
with 5% CO2 before 200 µL of media was removed and replaced with 100 µL of media
containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). This
media/MTT solution contained MTT at 5 mg/mL diluted 1:10 in DMEM. The plate was
10

incubated for four hours in the dark (wrapped in foil) at 37˚C with 5% CO2. After
incubation, 50 µL of media was removed from wells and replaced with 16% sodium
dodecyl sulfate/DMSO solution and mixed thoroughly to solubilize any formazan
produced. The plate was incubated again for ten minutes then the absorbance of
formazan production was read on a plate reader at 540 nm to determine mitochondrial
metabolism of treated cells in comparison to the non-treated cells.
Cellular Thermal Shift Assays
In attempt to better understand cinnamaldehyde’s antimicrobial mechanism
of action against S. aureus, cellular thermal shift assays (CETSA) were utilized. To do
this, 100 mL of 16-hour S. aureus cultures were pelleted for 10 minutes at 4150 rpm.
These pellets were re-suspended in 6.5 mL of PBS each, and transferred to 15 mL falcon
tubes. To each tube, two tablets of PierceTM Protease Inhibitor cocktails (Thermo
ScientificTM) and 2.5 mL of Lysostaphin (2 mg/mL stock in 20 mM sodium acetate) were
added. Samples were incubated for 30 minutes at 37˚C in a water bath, then 200 µL of
DNaseI was added, and tubes were incubated for another 30 minutes at 37˚C. Tubes
were centrifuged at maximum speed (15000 x g) twice, first for ten minutes, then the
supernatant (transferred into fresh 15 mL tubes) was centrifuged again for 20 minutes.
After centrifugation, 12 mL of supernatant was aliquoted into three fresh 50 mL tubes,
taking care not to disturb the insoluble pellet. The three test conditions that each falcon
had were: DMSO negative control, Trimethoprim positive control at 10 µg/mL and
cinnamaldehyde treatment condition at 420 µg/mL. These three samples were incubated
on ice for ten minutes, before 1 mL was removed and added to microfuge tubes (5
technical replicates per condition) and incubated in a heat block at either 37˚C or 55˚C
11

for three minutes. Samples were then ultra-centrifuged for 20 minutes at 200,000 x g.
After centrifugation, 900 µL of the supernatants was removed and placed into fresh tubes
incubated on ice. Protein concentrations for samples from all three test conditions were
quantified using a Pierce 600 nm assay kit, with a standard curve in PBS. Supernatants
were stored at -80˚C until processing via FASP purification (filter aided sample
preparation).
To FASP samples, 200 µL of 8M Urea was added to the tubes and together were
transferred to FASP filters. These tubes were centrifuged at 12,000 x g for fifteen minutes.
The samples were replaced into filters and centrifuged again but for ten minutes instead
of fifteen. After centrifugation, 100 µL of 50 mM iodoacetamide (prepared in 8M Urea)
was added to filters and incubated in the dark for twenty minutes. After incubation,
samples were centrifuged at 12,000 x g for ten minutes. Another 100 µL of 8M Urea was
added to each sample and centrifuged as before. This was repeated two more times. An
additional 100 µL 50 mM ABC (ammonium bicarbonate) was added to filters and
centrifuged as before. This was repeated for a total of three additions. Trypsin/LysC (20
µg lyophilized Trypsin-LysC mix, Promega) was added to samples at 1:50 (w:w,
trypsin:protein). Samples were then incubated at 37˚C for sixteen hours. After incubation,
filters were transferred to new collection tubes and gently vortexed (~650 rpm) for one
minute. These samples were then centrifuged at 12,000 x g for ten minutes. Next, 50 µL
of 50 mM ABC was added and centrifuged as before. This was repeated for a total of two
additions. Finally, 50 µL of 500 mM NaCl was added and tubes were centrifuged as
before. Samples were acidified with 10% TFA (trifluoroacetic acid) to a final concentration
of 0.5%. Samples then underwent desalting and finally were run on a Q Exactive™ Plus
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Hybrid Quadrupole-Orbitrap™ Mass Spectrometer. The resulting data was analyzed
using LFQ (label free quantification) intensity values and FASTA headers in MaxQuant
and Perseus software. The imputed values were log transformed to remove any invalid
‘0’ values. Exclusions were made by examining 33% of the data. A paired t-test was used
to analyze proteins that had a significant change in abundance in the treatment conditions
at 57˚C in comparison to at 37˚C.

Results

Antimicrobial Efficacy of Cinnamaldehyde against the ESKAPE Pathogens
Due to the toxicity of its aldehyde structure, cinnamaldehyde has been used
as antimicrobial agent against a plethora of bacteria. In order to determine the
antimicrobial effectiveness of cinnamaldehyde against the ESKAPE pathogens, MIC
assays were performed (Table 2). We found that the MIC is >210 µg/mL and <420 µg/mL
for E. faecium, S. aureus, K. pneumoniae and E. cloacae, >105 µg/mL and <210 µg/mL
for A. baumannii, and >420 µg/mL and <630 µg/mL for P. aeruginosa. Once the MICs
were established, MBC assays were performed to elucidate whether cinnamaldehyde
was bactericidal or bacteriostatic against the ESKAPE pathogens. The upper inhibitory
concentration was used as the 1X MIC value tested for bactericidal action. MICs assays
with this value, alongside 4X MIC and 0X MIC (DMSO control) were diluted in PBS and
plated onto TSA plates in duplicate. Percent recovery values were calculated based on
CFU/mL between treatment and no treatment samples, revealing that cinnamaldehyde
limits recovery of the ESKAPE pathogens to less than one percent at 1X MIC, and no
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recovery for all pathogens at 4X MIC, except P. aeruginosa and E. cloacae; which
displayed <1% recovery at this concentration. Since there is less than one percent
recovery at the MIC, cinnamaldehyde is considered bactericidal against the ESKAPE
pathogens. (Figure 1). To better understand the effect of cinnamaldehyde on bacterial
cells found in biofilms of the ESKAPE pathogens, MBEC assays were performed.
Although there was a greater percent recovery from MBEC assays in comparison to MBC
tests, there was still <50% recovery of bacterial cells treated with cinnamaldehyde from
the biofilms at 1X the MIC for all ESKAPE pathogens except S. aureus which had >50%
recovery at 1X MIC (Figure 2). At 4X MIC, there was <1% recovery for E. faecium, S.
aureus, and A. baumannii and no viable cells for K. pneumoniae, P. aeruginosa, or E.
cloacae at this concentration.
Synergistic Activity of Cinnamaldehyde and Commercial Antibiotics
In order to help elucidate the mode of action of cinnamaldehyde against the
ESKAPE pathogens, antibiotics with known antibacterial mechanisms of action were used
synergistically with cinnamaldehyde against A. baumannii and S. aureus (Table 3). The
antibiotics that showed synergistic activity with cinnamaldehyde against A. baumannii
were Doxycycline, Rifabutin and Triclosan. All the antibiotics used against S. aureus,
Rifabutin, Tetracycline, Vancomycin, Gentamicin, and Chloramphenicol showed
synergistic activity with cinnamaldehyde. It was concluded that there are many possible
mechanisms of action that cinnamaldehyde could be using to inhibit these pathogens.
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Stepwise Mutation Assays Reveal a Lack of Bacterial Adaptation to the
Antimicrobial Effects of Cinnamaldehyde
The striking characteristic of the ESKAPE pathogens is their multi-drug
resistant nature. Thus, adaptive mutation assays were performed to assess whether
cinnamaldehyde is an antibacterial treatment that these pathogens can develop
resistance to. It was found that after just a single two-fold increase in cinnamaldehyde
concentration above the MIC, growth of S. aureus and A. baumannii was completely
inhibited and continued to be so for the remainder of the experiment. Yet, S. aureus and
A. baumannii adapted and continued to grow even with continuous two-fold increase in
concentration of Vancomycin and Tetracycline, respectively (Figure 3). We conclude that
cinnamaldehyde’s mechanism of action did not allow for S. aureus or A. baumannii to
mutate in an adaptive manner to the treatment as it did for the commercial antibiotics.
Therefore, the biocidal action of cinnamaldehyde disables both Gram-positive and Gramnegative pathogens from gaining resistance.
Cytotoxic Activity of Cinnamaldehyde Against Human Cells
Ensuring not only efficacy against bacterial cells, but also the safety of
cinnamaldehyde against human cells is vital. Therefore, cinnamaldehyde was tested
against HEK 293 cells using an MTT assay to elucidate the compound’s cytotoxicity
through measuring mitochondrial activity of the cells (85). The maximal inhibitory
concentration, or IC50 was determined to be 38.25 µg/mL calculated using linear
regression. (Figure 4). The IC50 value represents the concentration of cinnamaldehyde
needed to inhibit 50% of cellular mitochondrial activity, presumably correlating to cellular
viability. When cells no longer convert MTT to formazan, they no longer appear deep
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purple in color but are instead yellow and are assumed dead. At ESKAPE pathogen MICs
of 105 µg/mL to 420 µg/mL, the HEK 293 cells had >50% inhibition of cellular functioning
meaning cell death occurred at these concentrations.
Proteomic Study of S. aureus with Cinnamaldehyde Treatment
Cellular thermal shift assay was performed using S. aureus to illuminate
which proteins may be targets for cinnamaldehyde within bacterial cells. S. aureus was
used specifically due to our preexisting knowledge of its proteome, and its ease of
manipulation. In total, five technical replicates from six different conditions were analyzed
by mass spectrometry. These were: Trimethoprim, cinnamaldehyde, and DMSO as a
control, with each condition tested at both 37˚C and 57˚C. The purpose of the heat shock
was to reveal which proteins remained stable during drug exposure, suggesting they were
interacting with, and thus were the target of, the relevant compound. Trimethoprim was
used alongside cinnamaldehyde as a positive control as its target is already well
characterized: in S. aureus it interacts with dihydrofolate reductase (86). Once samples
were analyzed by mass spectrometry and imputed in Maxquant and Perseus software,
the data revealed that 353 proteins were identified across the samples tested. For the
Trimethoprim conditions, 199 proteins had higher relative abundance at 37˚C while 154
proteins had higher abundance at 57˚C, of which 90 had >1.5-fold increase at 57˚C
(Figure 5). The Trimethoprim test condition at 57˚C was further examined for significant
relative abundance of proteins in comparison to the Trimethoprim test condition at 37˚C.
After running a paired t-test, the relative abundance of seven proteins were found
significant at 57˚C (Figure 6). Despite a 3.7-fold increase in dihydrofolate reductase
abundance in the Trimethoprim 57˚C condition in comparison to the control 57˚C
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condition, this protein was not one of the seven statistically significant proteins found in
these conditions (p = 0.1). A potential reason for this protein falling outside the range of
significance may be due to a function of the data analysis process in Perseus, where
calculated values are imputed for any null values. Changes in the percent of samples
analyzed could adjust the significance of relative abundance values.
In the cinnamaldehyde condition, 107 proteins had higher relative
abundance at 37˚C while 246 proteins had higher abundance at 57˚C, of which 206 had
>1.5-fold increase at 57˚C (Figure 7). Like the Trimethoprim test condition, the
cinnamaldehyde samples at 57˚C was further examined for significant relative abundance
of proteins in comparison to the cinnamaldehyde samples at 37˚C. After running a paired
t-test, the relative abundance of 36 proteins were found significant at 57˚C (Figure 8).

Discussion

Through the work of ourselves and others, cinnamaldehyde has shown
promise in being a bactericidal antimicrobial agent to inhibit the ESKAPE pathogens. The
antimicrobial activity of cinnamaldehyde against other pathogens has been shown
previously (30). The MICs of cinnamaldehyde against the ESKAPE pathogens
determined in this research fall within the upper and lower concentrations of MICs already
found for cinnamaldehyde against P. aeruginosa, A. baumannii, S. aureus and K.
pneumoniae. Specifically, we found that cinnamaldehyde inhibited P. aeruginosa
between 420 and 640 µg/mL. In literature, multi-drug resistant P. aeruginosa strains have
MICs of cinnamon bark essential oil between 525 µg/mL and 2.3 mg/mL, with the main
17

constituent of this oil being cinnamaldehyde (22). Another group found that
cinnamaldehyde

inhibited

an

expanded

spectrum

beta-lactamase

producing,

cephalosporinase-overproducing, multi-drug resistant A. baumannii strain with a MIC at
310 µg/mL (31). Our strain of A. baumannii had shown cinnamaldehyde to have a lower
MIC, which fell between 105 and 210 µg/mL. Shen et al. found cinnamaldehyde to have
the same MIC of 310 µg/mL against an ATCC strain of S. aureus (32), which falls directly
between the upper and lower concentration that our S. aureus MIC was between 210 and
420 µg/mL. A non-pathogenic strain of K. pneumoniae exhibited inhibition by
cinnamaldehyde at the MIC of 62.5 µg/mL (33). Comparatively, this concentration is much
lower than our MIC finding for K. pneumoniae which was between 210 and 420 µg/mL.
Former research, to our knowledge, has not been done with cinnamaldehyde inhibiting
E. faecium or E. cloacae and therefore the MICs between 210 and 420 µg/mL for these
pathogens are novel findings.
We have shown that cinnamaldehyde not only has inhibitory concentrations
in the microgram range, but also has high bactericidal qualities at these same
concentrations against the ESKAPE pathogens. Jia et al. described discordant findings,
where six strains of S. aureus were tested and their cinnamaldehyde MBC was two to
four-fold higher than the MIC values (35). We found that cinnamaldehyde was bactericidal
at 1X MIC for all ESKAPE pathogens including S. aureus. This group also found that their
six S. aureus strains had less <50% recovery of viable cells from biofilm tests at 1X MIC,
while we found S. aureus to be the only ESKAPE pathogen that did not have that level of
biofilm eradication at 1X MIC. Thus, it is possible that biofilm eradication by
cinnamaldehyde is strain-dependent for S. aureus. We found that at 4X MIC, viable cells
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for biofilms from all pathogens were eradicated most likely due to the toxic nature of
cinnamaldehyde. Cinnamaldehyde is already being considered for medical industry
purposes for decreasing biofilm formations on catheters that are frequently the cause of
urogenic E. coli infections (34). Due to such high toxicity towards bacterial cells and
biofilms, it was unsurprising that S. aureus and A. baumannii did not adapt resistance to
cinnamaldehyde. This lack of ability to mutate could be due to multiple modes of
antimicrobial activity of cinnamaldehyde against the pathogens. To our knowledge,
adaptive mutation resistance assays have not been performed with cinnamaldehyde
against any ESKAPE strain, and therefore these are novel findings. In general, the ability
of pathogens to gain resistance against essential oils is not well investigated (36).
Checkerboard assays were performed to study the synergistic ability of
cinnamaldehyde and antibiotics to inhibit the ESKAPE pathogens at lower dosages, as
well as examine possible mechanism of action. It has been shown that an MDR strain of
P. aeruginosa was synergistically inhibited at a 10% higher rate when treated with
cinnamaldehyde and Colistin (22). Another group found synergistic activity when
cinnamaldehyde was used in conjunction with Ampicillin and Chloramphenicol against
ATCC strains of S. aureus and P. aeruginosa (37) K. pneumoniae has been tested for
inhibition by synergistic activity between cinnamaldehyde and Cefotaxime as well as
Ciprofloxacin and both exhibited synergism (38). Our findings show that out of the thirteen
antibiotics tested against S. aureus and A. baumannii, nine were synergistic with
cinnamaldehyde and were thus effective at lower dosages. All these findings show
possibility that antibiotics can be used in conjunction with cinnamaldehyde for therapeutic
treatments with fewer side effects. Due to the multiple antibiotics that cinnamaldehyde
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shows inhibitory synergism with, it is still unknown as to what the mechanism of action for
cinnamaldehyde is. In literature, cinnamaldehyde has been discussed to disrupt
membrane permeability, inhibit bacterial division through the essential FtsZ protein,
engender rRNA damage, disperse biofilm aggregation, and decrease expression of
resistance genes (39). Our findings demonstrate a similar idea that cinnamaldehyde may
be inhibiting bacteria through multiple synergistic modes of action from interacting with
RNA polymerase when used with Rifamycins (40), inhibiting cell wall formation with
Vancomycin (41), inhibiting fatty acid synthesis when combined with Triclosan (42), or,
the most likely mechanism, destabilizing membranes and facilitates easier access of
other antibiotics to their target.
While understanding mechanism of action is crucial in drug discovery, true
therapeutic relevance lies within the level of cytotoxicity novel compounds display towards
eukaryotic cells. Accordingly, cytotoxicity was tested using HEK 293 cells, revealing that
at ESKAPE pathogen MICs between 105 µg/mL and 620 µg/mL, cinnamaldehyde
inhibited mitochondrial functioning >50%. Stated another way, there was <50% viable
cells at these concentrations. Although to our knowledge cinnamaldehyde has not been
tested against HEK 293 cells, it has been shown to not be as cytotoxic when tested
against other cell types. These include murine macrophage, mouse neuroblastoma,
human osteosarcoma, human fibrosarcoma, mouse connective tissue, human cervix
carcinoma, human skin carcinoma, primary fibroblast, mouse hepatocytes and human
neuroblastoma cells (29). At cinnamaldehyde concentrations of 10 mg/mL, half of the
cells (murine macrophage, human osteosarcoma, human fibrosarcoma, mouse
connective tissue, mouse neuroblastoma) had >50% viability while the other half (human
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cervix carcinoma, human skin carcinoma, human neuroblastoma, primary fibroblast and
mouse hepatocytes) had <50% viability when the MTT assay was used to asses cell
viability. Only at 20 mg/mL did all ten cells have <50% viability. This decrease in
cinnamaldehyde cytotoxicity when tested against ten other cell lines does not coincide
with our findings and thus requires further investigation.
Proteomic analysis has shown that cinnamaldehyde disrupts lipid,
carbohydrate and amino acid metabolism in Cronobacter, a relative of the ESKAPE
pathogen Enterobacter (34). Cinnamaldehyde also affected cellular defense against
oxidative stress, motility, attachment and invasion ability of Cronobacter in epithelial and
macrophage cells when adhesion and invasion assays were performed (34). To better
understand if the mechanism of action cinnamaldehyde uses is related to binding to
specific proteins, CETSA assays were performed using S. aureus as a representative
ESKAPE pathogen. This assay uses the properties of protein denaturation to reveal which
proteins remain bound to ligands when the temperature is increased. Our CETSA data
reveals the relative abundance of 36 S. aureus proteins theoretically remained bound to
cinnamaldehyde when the testing condition increased to 57 ˚C. Of these proteins, the top
five most abundant are involved in glycolysis, protein synthesis, or cellular detoxification.
The wide range of function among the 36 proteins could be due to cinnamaldehyde having
multiple mechanisms of action, or, possible cross-linking between the aldehyde group of
cinnamaldehyde and S. aureus proteins.
Through our findings of the antimicrobial activity along with studies that
already have been done including low cytotoxicity in non-human kidney cells,
cinnamaldehyde has the potential to be a good candidate as a novel therapeutic
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treatment option for topical use through botanical means for treating deadly, multi-drug
resistant infections caused by the ESKAPE pathogens.

Future Directions

Any compound being considered as a novel therapeutic agent to treat
infections, requires extensive research to ensure its efficacy and safety. Therefore, there
is much exploration left to be done to better understand cinnamaldehyde’s mode of action
and cytotoxicity. We, amongst others, have found cinnamaldehyde to be antimicrobial
against pathogenic bacteria. To better understand the inhibitory mechanisms of action
this compound has against pathogens, transcriptomic and proteomic studies should be
conducted. Visvalingam et al. found that at sub-lethal concentrations of cinnamaldehyde
against E. coli O157:H7, cell replication was inhibited, and elongation occurred (43). Yet,
after two hours of treatment, cells reverted to normal size and began to grow again.
Another interesting finding was that cinnamaldehyde caused the expression of oxidativestress repression genes, and after four hours of cinnamaldehyde treatment, E. coli was
able to revert cinnamaldehyde to less toxic cinnamic alcohol and resume normal
functioning (43). These findings suggest that cinnamaldehyde could be affecting the
mechanics of cellular growth as well as causing toxicity within bacteria causing stress
response gene expression. In order to narrow down the mechanism of inhibition, gene
expression and proteomic analysis of multiple pathogens treated with cinnamaldehyde at
varying time points should be conducted. Another avenue to study pathogens when
treated with cinnamaldehyde, is by use of metabolomic analysis. This method maps out
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bacterial metabolic signatures through nuclear magnetic resonance (NMR) and mass
spectrometry analysis to better understand enzymes and substrates when treated with a
drug (44). Overall, cell-wide omics data will aid in understanding the molecular level
workings of drugs when treating infectious pathogens. This previously discussed research
is only the beginning of the drug discovery pipeline. Once the mechanism is fully
understood, in vivo studies for topical use of cinnamaldehyde are required. Consequently,
the future of cinnamaldehyde being used as an antimicrobial treatment option is not yet
a reality but based on data available to date, it has a promising possibility to be used
either topically, or synergistically with known antibiotics to treat ESKAPE infections.

Table 1: Clinical Isolate ESKAPE Pathogen Strains and Origins
Pathogen

Strain

Provenance

Origin

Enterococcus faecium

1450

Moffitt Cancer Center

Rectum

Staphylococcus aureus

635

Tampa General Hospital

Blood

Klebsiella pneumoniae

1433

Moffitt Cancer Center

Urine

Acinetobacter baumannii

5075

Walter Reed Army Medical Center

Unknown

Pseudomonas aeruginosa

1419

Moffitt Cancer Center

Respiratory

Enterobacter cloacae

1454

Moffitt Cancer Center

Urine

Table 2: ESKAPE Pathogen Growth Inhibition by Cinnamaldehyde. Listed are the
MICs as an approximation between two concentrations due to the serial dilution method.
The actual inhibitory concentration falls somewhere in between these two concentrations.
Pathogen

MIC

E. faecium

>210 and ≤420 µg/mL

S. aureus

>210 and ≤420 µg/mL
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Table 2 (Continued)
K. pneumoniae

>210 and ≤420 µg/mL

A. baumannii

>105 and ≤210 µg/mL

P. aeruginosa

>420 and ≤630 µg/mL

E. cloacae

>210 and ≤420 µg/mL

Figure 1: Bactericidal Activity of Cinnamaldehyde Against the ESKAPE Pathogens.
The upper MIC value was used as the 1X concentration of each pathogen alongside the
4X MIC and DMSO 0X control. At 1X MIC, there is <1% recovery for all the ESKAPE
pathogens. Error bars are shown ±SEM from six technical replicates.
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Figure 2: Biofilm Eradication by Cinnamaldehyde. Cinnamaldehyde eradicates >50%
of the bacterial cells from biofilms at 1X MIC of all the ESKAPE pathogens except for S.
aureus. This pathogen exhibits >50% biofilm eradication between 1X and 4X MIC
concentration. Error bars are shown ±SEM from six technical replicates.

Table 3: Synergistic Activity Between Cinnamaldehyde and Antibiotics of Known
Mechanism of Action Against A. baumannii and S. aureus. The following antibiotics
were combined with cinnamaldehyde and tested at MIC values of both treatments, and
then serially diluted and tested at the subsequent concentrations. The lowest
concentration of each treatment that showed full inhibition of the pathogens were chosen
to calculate the FIC Index.
ESKAPE

Treatment

FIC Index

Interpretation

A. baumannii

Ciprofloxacin

1.0

Indifference

A. baumannii

Polymyxin B

0.65

Indifference
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Table 3 (Continued)
A. baumannii

Doxycycline

0.07

Synergy

A. baumannii

Rifampicin

2.0

Indifference

A. baumannii

Rifabutin

0.07

Synergy

A. baumannii

Triclosan

0.50

Synergy

A. baumannii

Rifamycin

0.51

Indifference

S. aureus

Rifabutin

0.02

Synergy

S. aureus

Tetracycline

0.14

Synergy

S. aureus

Vancomycin

0.5

Synergy

S. aureus

Gentamicin

0.05

Synergy

S. aureus

Daptomycin

0.38

Synergy

S. aureus

Chloramphenicol

0.38

Synergy
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Figure 3: S. aureus and A. baumannii are Unable to Develop Resistance to
Cinnamaldehyde. After eight days of being passaged through two-fold increases in
concentration of cinnamaldehyde and antibiotic treatment, neither S. aureus nor A.
baumanii became resistant to cinnamaldehyde while they did become resistant to
antibiotic treatment.
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Figure 4: Cinnamaldehyde is Cytotoxic to HEK 293 Cells at Concentrations Below
S. aureus and A. baumannii MICs. An MTT assay was used to determine that the IC50
of cinnamaldehyde against HEK 293 cells is 38.25 µg/mL. Error bars are shown ±SEM
from three technical replicates.
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Figure 5: Relative Abundance of S. aureus Proteins when Treated with
Trimethoprim and Heat Shocked. At both temperature conditions of 37˚C and 57˚C,
the mean of each proteins five replicate LFQ intensity values were compared. The xaxis represents all 353 proteins found in the sample by mass spectrometry. The color
scale represents the relative abundance of each protein isolated in the samples.
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Figure 6: Relative Abundance of Significant Altered Proteins During Trimethoprim
Treatment and Heat Shock at 57˚C. A paired t-test was used to determine which
proteins had increased fold changes in the 57˚C heat shock condition in comparison to
the 37˚C condition. Error bars are shown ±SEM from five technical replicates.
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Figure 7: Relative Abundance of S. aureus Proteins when Treated with
Cinnamaldehyde and Heat Shocked. At both temperature conditions of 37˚C and 57˚C,
the mean of each proteins five replicate LFQ intensity values were compared. The x-axis
represents all 353 proteins found in the sample through mass spectrometry. The color
scale represents the relative abundance of each protein isolated in the sample.
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Figure 8: Relative Abundance of Significant Altered Proteins During
Cinnamaldehyde Treatment and Heat Shock at 57˚C. A paired t-test was used to
determine which proteins had increased fold changes in the 57˚C heat shock condition
in comparison to 37˚C condition. Error bars are shown ±SEM from five technical
replicates.
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Chapter 2: Exploring the Microbial Ecology of Diverse and Underexplored
Geographic Locations for Novel Secondary Metabolite Acquisition
Introduction

The Challenges of Environmental Microbial Ecology
The world around us is surrounded by an active invisible community. This
community is made up of bacteria, viruses, and fungi that are communicating amongst
themselves and with the surrounding biota. Together, these communities thrive and act
like small ecological cities that not only surround us but colonize us as well. Many aspects
of microbial ecology are being studied by the scientific community to gain a better
understanding of its function, structure, and nutrient cycling (45). The first scientist to
study the soil for microbial ecology was Selman Waksman (46). His methodology was to
collect soil samples and culture microbes that could adapt to laboratory conditions and
grow. His most famous finding was the isolation of the Streptomycin-producing
Actinobacteria Streptomyces griseus. His findings were the catalyst for environmental
microbiology studies especially in the search for antibiotic producing microbes.
Studying microbial ecology over the past century in laboratory conditions
has proven difficult because bacteria behave differently in the natural environment versus
laboratory conditions. Therefore, culture-dependent studies are limited by the number of
microbes that can adapt and grow in the lab. Even if these microbes can be cultured in
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the lab, they do not necessarily function the same as they would in nature since
environmental factors and community members are not available to turn on and off the
microbe’s plethora of metabolic processes. Culture-independent approaches, which
include metagenomic studies characterizing entire soil samples, are limited by not
working with live growing cultures, but only nucleic acids (45). A problem with this avenue
is that the metabolomic studies are not possible and these studies do not show the true
living microbial community, only the DNA found within the sample. One of the final
obstacles for microbial ecology research is the collection of samples (47). The
environment is under constant flux due to weather, nutrient changes, and human
involvement that directly affect microbial communities. These three challenges have been
shown to be the limiting factor in tapping into the goldmine of natural products and
biosynthetic gene clusters that can be found in the environment.
Crucial Need for Microbial Bioactive Metabolites
Despite the challenges of studying the microbial environment around us,
this frontier needs immediate exploration because the world is on the brink of a possible
post-antibiotic era (48). Seemingly simple illnesses like bronchitis or streptococcal
pharyngitis may soon be lethal due to antibiotic resistance (49). One cause of this threat
is the rapid mutation of pathogens caused by the over- and misuse of antibiotics (19).
Another problem is the lack of profit that comes with antibiotic production (50). The nature
of antibiotics is to treat short-term infections. This differs greatly to medications that are
used to treat chronic illnesses such as diabetes, or those requiring psychotropic
medications. Pharmaceutical companies find the return on investment to produce one
antibiotic that is not used with regularity by the masses is not very strong (49). While
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research is being done to synthetically create antibiotics; nature shows more promise for
finding antibiotics (51). More than 120 important medications used today come from
terrestrial microbes (47). Yet, 86% of terrestrial microbes are not yet characterized (52).
Even with much left to be discovered from terrestrial microbiomes, the study of marine
microbes and their antimicrobial secondary metabolites is increasing due to the need to
find new antibiotics, and the past success of those that have already been discovered. In
the late 1990’s, over 7100 metabolites derived from marine organisms were characterized
(47). Of the microorganisms that produced these metabolites, 23% were isolated from
sediment and 47% were isolated from invertebrates (47). It is believed that these
metabolites were derived from only 9% of the ocean’s microbiome (52). Overall, with
many marine microorganisms left to be discovered, the ocean’s microbiome is a reservoir
of potential genes coding secondary metabolites to be used for medicinal purposes (51).
Microbial Warfare by Secondary Metabolites
Natural microbial communities are in constant warfare with one another
over both space and nutrients (53). Fungi, bacteria, and other microbes secrete
secondary metabolites that are used as defense mechanisms against invasive or
encroaching organisms and confer the producers with competitive advantages (54).
These metabolites are created late in growth, after primary metabolites are produced.
Primary metabolites are used for common cellular processes while secondary metabolites
are not always produced by microbe but are turned on only in response to certain
circumstances, such as changes in nutrients, temperature, and quorum sensing with
other microbes (55). Primary metabolites are used by microbes to synthesize secondary
metabolites, which include peptides, carbohydrates, lipids, terpenoids, and alkaloids (54).
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With the continued rise of drug resistant bacteria, such secondary metabolites can be
harnessed for the discovery and development of potential future antibiotics (18).
Approximately 60% of all the known bioactive microbial metabolites, around 14,000
compounds, have antimicrobial activity (56). Most of these secondary metaboliteproducing bacteria arise from the marine environment. Within this environment, the
pelagic and benthic zones have major diversity in terms of bacterial ecology residing in
each region (57). In this study, it is the marine sediment and not the water column that is
being investigated for bacterial diversity and secondary metabolite acquisition.
Marine Bacterial Diversity
The amount of bacterial diversity that exists in the ocean is still largely
unknown (51). It is believed that 91% of marine microbial species have not yet been
characterized, therefore, many novel compounds to be derived from these microbes are
left undiscovered (52). Molecular studies show that marine microbial diversity varies
greatly in different geographic regions (58). Understanding the microbial diversity in
distinct regions proves to be a difficult task due to several factors. One difficulty is that
less than 1% of environmental microbes are culturable in the laboratory setting adding a
limiting factor to the amount of manipulatable environmental microbes that exist (59).
Conversely, environmental samples can undergo metagenomic studies by sequencing
the 16S genes to demonstrate diversity; yet, it is unknown whether the bacterial DNA
being sequenced is representative of viable bacteria from the sample or whether genetic
material from non-resident bacteria contaminated the sample. Another difficulty in
studying microbial diversity is the lack of a universally accepted definition of a species
when analyzing mass phylogenetic datasets (60). While there are those that wish to
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identify species based on a >97% rDNA identity match, others suggest that doing this
would be the synonymous to combining all primates (from humans to lemurs) into one
category if this method was used for mammalian speciation (58). Consequently, not only
DNA identity, but metabolism, phenotypic data, and the ways that bacteria react to their
environments also need to be considered in the characterization process of new isolates
(58).
Phylogenetically speaking, sediment has the most diversity of all other
environments studied to date (61). In terms of environmental factors, one study showed
that salinity, more so than temperature and pH, affects the microbial diversity of sediment
samples (62). In this study, sediment samples were taken from three geographic regions
that, according to NASA’s Aquarius satellite that orbits the earth measuring ocean salinity,
shows that these regions could have up to 1g/kg difference in salinity (63). Therefore,
the aim of this study is to investigate microbial diversity of understudied marine
geographic regions to potentially unlock microbial bioactive compounds. To accomplish
this, microbes were cultured from marine sediment samples retrieved from Hawaii, the
Gulf of Mexico, and Antarctica. Growth conditions were optimized to mimic marine
environments, and to specifically encourage growth of Actinobacteria. Isolates that were
able to adapt to the lab and grow were then characterized by sequencing the 16S-23S
region and were tested for secondary metabolite production. Secondary metabolites were
extracted using ethyl acetate after a two-week growth period in both high and low nutrient
media. These crude extracts were then re-solvated in DMSO and tested for antimicrobial
activity against clinical isolates of the ESKAPE pathogens.
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Materials and Methods

Microbial Isolation and Characterization
Marine Sediment Collection
A total of six sediment samples were used to isolate environmental
microbes. Three samples were collected from the Gulf of Mexico (Midflorida Diving
Grounds, 2015), two were collected from Hawaii (Kalapaki, 2018; Waimea Bay, 2018)
and one was collected from Antarctica (East Arthur Harbour, 2016).
Growth Media
All media was prepared using deionized (DI) water and sterilized by
autoclaving. ISP-2 agar plates were supplemented with antibiotics to discourage the
growth of fungi. These antifungals were: cycloheximide at 50 µg/mL and nystatin at 50
µg/mL. The following are recipes used to make each media per liter of DI water.
AMM
10 g Soluble Starch
4 g Yeast Extract
2 g Peptone
36 g IO (Instant Ocean®)
18 g Agar

ISP-2 (International Streptomyces Project-2)
10 g Malt Extract
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4 g Glucose
4 g Yeast Extract
15 g Agar
0.38 g Tyrosine
36 g IO (Instant Ocean®)

Starch Casein Broth (SCB)
1 g Casein
10 g Soluble starch
2 g Potassium nitrate (KNO3)
15 g Agar

Tryptic Soy Broth (TSB)
30 g Tryptic Soy Broth

Tryptic Soy Agar (TSA)
30 g Tryptic Soy Broth
15 g Agar

Mueller Hinton Broth II (MHB II)
22 g Mueller Hinton Broth II
Inoculation and Culturing Techniques
Method 1 –
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A total of 5.0 g of wet sediment sample was weighed in a petri dish and dried
overnight in a sterile laminar flood hood. Autoclaved sponge bungs were used to stamp
AMM media plates in a clockwise serial dilution pattern after the flat edge was pressed in
dried sediment sample. AMM plates were wrapped in parafilm and incubated at room
temperature (25˚C) for 2 – 16 weeks.
Method 2 –
Half of the dried sediment from method 1 was added to a 15 mL centrifuge tube
with filter sterilized (0.22 µm pore filter) IO water at a ratio of 1:3 (water to sediment). The
mixture was vortexed then placed in a 55˚C water bath for seven minutes. The tube was
then vortexed for two minutes and centrifuged for ten minutes at 3700 x g. After vortexing
the tube, 100 µL of the supernatant was added to AMM plates and spread using sterile
beads. The plates were incubated in the same manner as in method 1.
Incubation Conditions
Freshly inoculated AMM plates were incubated in a combination of either
light or dark and with or without oxygen. Light conditions were left on the bench for
incubation while the dark condition was created by wrapping plates in foil. Anoxic
conditions were made by placing plates (either wrapped or not wrapped in foil) into a small
air-tight tank with BD GasPak®.
Isolation and Purification of Marine Isolates
After 2 – 16 weeks of incubation in the light/dark/oxygenic/anoxic
conditions, plates were visually analyzed, and phenotypically distinct colonies were
chosen for isolation and identification. Strains were subject to four rounds of isolation
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using ISP-2 media, with the final one employing a quadrant streak from which a single
colony was used to inoculate a 5 mL TSB tube. The isolate was then placed in a 30˚C
shaking incubator to grow for one week. After incubation, the isolate culture was stored
in a 20% glycerol solution at -80˚C until further experimentation was required.
Marine Isolate DNA Extraction
Chromosomal DNA extraction was performed on each of the isolates for the
purpose of identification. Isolates were grown from glycerol stocks on TSA plates for one
week followed by growth in 5 mL of TSB for another week. The bacteria were pelleted at
3700 x g for ten minutes, and the supernatant decanted before the bacteria were
resuspended in 600 µL of TE buffer. Once resuspended, 600 µL of this solution was
added to 2 mL screw capped centrifuge tubes that were filled 1/8th full of 0.1 mm sterile
disruption beads. Cells were then lysed by bead beating for 30 seconds, four times with
a one-minute break between each lysis round. The tubes were then centrifuged at 17,000
x g for five minutes and the supernatant was carefully removed and aliquoted into sterile
1.5 mL Eppendorf tubes. To each tube, 5 µL of Proteinase K and 100 µL of 1.6% Sarkosyl
was added. These tubes were inverted to mix and placed in a 60˚C incubator for 1 – 24
hours. After incubation, 600 µL of phenol chloroform was added to each tube, inverted to
mix, and centrifuged for five minutes at 17,000 x g. The clear, upper, aqueous layer was
carefully removed (without disturbing the bottom layer) and added to new sterile 1.5 mL
Eppendorf tubes. To each of these tubes, 500 µL of 100% Isopropanol and 100 µL of
Sodium Acetate was added. The tubes were again inverted to mix and then placed at 80˚C for 0.5 – 24 hours. Still frozen, the tubes were centrifuged for ten minutes at full
speed. Promptly after centrifugation, the supernatant was carefully removed and
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discarded leaving behind the DNA pellet. After the supernatant was removed, 50 µL of
70% Ethanol was added to each pellet and the tubes were centrifuged again, this time for
five minutes at 17,000 x g. The supernatant was removed and discarded, and the tubes
were left open on the bench to dry for five minutes. DNA pellets were resuspended in 100
µL of RNA water and stored at 4˚C until used for PCR.
PCR Amplification and Sequencing
Marine sediment isolates from the glycerol library were characterized by
amplifying the 16S-23S rRNA region of their genomes by PCR followed by Sanger
sequencing. Each PCR tube was prepared by adding 9.5 µL of RNA water, 1 µL of DNA
at a concentration of 50 – 500 ng/µL, 12.5 µL of LongAmp® Taq DNA Polymerase, 1 µL
of forward primer (5′-CAGCMGCCGCGGTAA-3′), and 1 µL of reverse primer (5′CCRAMCTGTCTCACGACG-3′) (64). PCR thermocycling conditions were:
Initial Denaturation: 94˚C (5 minutes)
94˚C (30 seconds)

35 Cycles of:

60˚C (30 seconds)
65˚C (5 minutes)
Final Extension:

65˚C (10 minutes)

Hold:

4˚C (infinite)
After amplification, PCR products were then cleaned using UPrep® Spin

Columns. To each PCR tube 100 µL of PB buffer was added to the amplified product and
the entire solution was transferred into the column. These tubes were incubated for one
minute at room temperature (25˚C) and then centrifuged at 8000 x g for one minute. The
eluates were replaced onto the columns’ membranes to repeat this previous step two
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more times. This resulted in the PCR products being passed through the membranes a
total of three times. The columns were then washed with 300 µL of PE buffer with the
same centrifugation settings used previously. Once centrifuged, the eluates were
discarded, and the spin columns were dried by centrifuging at 5000 x g for one minute. In
order to elute the DNA from the columns, the columns were transferred from the original
tubes to sterile 1.5 mL Eppendorf tubes and 30 µL of RNA water was added to the
membranes. The tubes were incubated at room temperature for one minute, then
centrifuged for one minute at 8000 x g. The eluates were replaced back into the column
and this step was repeated two more times for a total of three passages through the
columns. The columns themselves were discarded and the tubes containing the cleaned
PCR products were stored at 4˚C until ready for sequencing. All sequencing was
performed by GeneWiz® and results were analyzed using BLAST® (optimize for blastn).
Secondary Metabolite Extractions
Marine sediment isolates were struck from their glycerol stock onto TSA
plates and incubated at room temperature for one to two weeks. Each isolate was then
inoculated into glass, baffled flasks containing 30 mL of TSB or SCB. These flasks were
placed into a 30˚C shaking incubator to grow for two weeks. After the two-week growth
period, if media was not noticeably turbid, bacterial growth was confirmed by spot plating
30 µL onto TSA plates, incubating for one to two weeks at 30˚C, and being observed for
growth. To begin the extraction process, 20 mL of ethyl acetate was added to each flask
and placed back into the shaking incubator for one hour. The cultures were filtered using
a glass funnel and coffee filters to remove the unwanted proteinaceous layer. Once
filtered and replaced in the original growth flask, the upper ethyl acetate layer containing
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secondary metabolites was carefully removed using a 9’’ glass Pasteur pipet into a preweighed 20 mL glass scintillation vial. Another 15 mL of ethyl acetate was added to the
now acetone-depleted flask, swirled, and left to sit in the fume hood for 24 hours. The
upper ethyl acetate layer was again removed using a glass pipet and added to same
scintillation vial used in the first extraction round. After the second extraction, the
scintillation vials were dried down, by removing caps and air drying in a laminar flow hood,
weighed, and extracts resolubilized in DMSO to 5 mg/mL for antimicrobial testing. Vials
containing DMSO and extracts were stored at room temperature.
Testing Antimicrobial Activity of Extracts Against ESKAPEs
To test the inhibitory activity of the microbial extracts, the broth microdilution
method was used. Each extract was tested against all ESKAPE pathogens, first only
singularly, and if there was activity, then in triplicate. In each testing well of the 96-well
plate, 96 µL of broth, 4 µL of 5 mg/mL or 10 mg/mL extract, and 100 µL of bacteria diluted
1:1000 was added. Different broth was used depending on the ESKAPE pathogen tested.
TSB was used with first two pathogens: E. faecium and S. aureus, and MHBII was used
for the last four pathogens: K. pneumoniae, A. baumannii, P. aeruginosa, and E. cloacae.
The 96-well plates were placed in the 37˚C shaking incubator for 18 – 24 hours and
checked for antimicrobial activity by visual inspection of clear or turbid wells.

Results

Microbial Ecology of Diverse Geographic Locations
Methods Used to Encourage Growth
A total of six different marine sediment samples taken from three different
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locations were used to study microbial ecology. Three of the samples were collected
from the Gulf of Mexico, with an additional two being collected from Hawaii, and the final
sediment sample coming from Antarctica. Twenty-four AMM plates were incubated per
sediment sample according to the distinct culturing methods described above. After a
two-week incubation period, phenotypically distinct colonies were chosen for isolation
rounds. There were four rounds of isolation, with each round requiring at least one week
of growth. Therefore, the process in total from inoculation of original AMM plates to
having a glycerol stock of a single isolate took six to eight weeks. Once stored in
glycerol at -80˚C, isolates were struck onto TSA plates to check again for purity, since
many of the microbes grew synergistically and were difficult to distinguish amongst one
another. Of the 293 microbes purified and stored, 126 were isolated from the Hawaii
sediment, 103 were isolated from the Gulf of Mexico sediment samples, and 64 were
isolated from the Antarctica sediment sample.

Characterization of Geographically Diverse Marine Isolates

Bacteria isolated from Hawaii, the Gulf of Mexico and Antarctica were characterized
using DNA extraction, PCR amplification of the 16S-23S rRNA gene, and Sanger
sequencing. The top hits of sequencing results for each location are described below.
Thus far, from the sediment samples analyzed, there were 52 isolates characterized
from the Antarctica (Table 4), 111 isolates characterized from Hawaii (Table 5), and 94
isolates characterized from the Gulf of Mexico (Table 6).The isolate genera cultured
from Antarctic marine sediment were: Agrococcus sp., Arthrobacter sp., Chelativorans
sp., Corynebacterium sp., Dietzia sp., Micrococcus sp., Nitratireductor sp.,
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Rhodococcus sp., Salinibacterium sp., Sporosarcina sp., and Staphylococcus sp. The
relative abundance of each of these is shown below in Table 4 with Nitratireductor sp.
being the most frequent isolate cultured. The isolate genera cultured from Hawaiian
marine sediment were: Brevibacterium sp., Arthrobacter sp., Bacillus sp., Enterococcus
sp., Fictibacillus sp., Lysinibacillus sp., Marinobacter sp., Nitratireductor sp.,
Oceanobacillus sp., Paenibacillus sp., Pseudomonas sp., Rummeliibacillus

sp.,

Solibacillus sp., Sporosarcina sp., Staphylococcus sp., Stenotrophomonas sp., and two
uncultured microbes. Two of the most abundant genera cultured from the Hawaiian
sediment samples were Bacillus sp. and Marinobacter sp.. The isolate genera cultured
from the Gulf of Mexico marine sediment were: Brevibacterium sp., Arthrobacter sp.,
Aureimonas sp., Bacillus sp., Chelativorans sp., Curtobacterium sp., Fictibacillus sp.,
Halomonas sp., Kocuria sp., Marinobacter sp., Nitratireductor sp., Ochrobactrum sp.,
Phyllobacterium sp., Psycrobacter sp., Rhizobium sp., Staphylococcus sp., and two
uncultured microbes. Of these genera, the most abundant was Nitratireductor sp.. The
different genera found in each geographic region in comparison to one another is shown
below (Figure 9). Nitratireductor, Arthrobacter, and Staphylococcus were the only three
genera cultured from all three distinct regions. The five genera isolated from both the Gulf
of Mexico and Hawaii sediment samples were: Brevibacterium, Bacillus, Fictibacillus,
Marinobacter, and Uncultured bacteria. The two genera isolated from both Gulf of Mexico
and Antarctica sediment samples were: Chelativorans and Micrococcus. The only genera
isolated from both Antarctica and Hawaii sediment samples was Sporosarcina. The only
genera isolated solely from the Gulf of Mexico sediment samples were: Aureimonas,
Curtobacterium, Halomonas, Kocuria, Ochrobactrum, Phyllobacterium, Psychrobacter,
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and Rhizobium. The only genera isolated solely from the Hawaii sediment samples were:
Enterococcus,

Lysinibacillus,

Oceanobacillus,

Paenibacillus,

Pseudomonas,

Rummeliibacillus, Solibacillus, Stenotrophomonas, Streptomyces, and Terribacillus.
Finally, the only genera isolated solely from Antarctica sediment samples were:
Agrococcus,

Corynebacterium,

Dietzia,

Rhodococcus,

Salinibacterium,

and

an

unidentified Actinobacterium.
Secondary Metabolite Acquisition and Testing for Antimicrobial Activity
Once purified and stored as a glycerol library, the secondary metabolites of
isolates were tested for antimicrobial activity against the ESKAPE pathogens. Thus far
266 isolates have undergone extractions following growth in TSB while 241 isolates have
undergone extractions following growth in SCB. These extracts have all been tested
against the ESKAPE pathogens for antimicrobial activity (Table 7). Upon assessing the
two different growth conditions (nutrient rich and nutrient poor) and testing the effect of
their secondary metabolite activity against the ESKAPE pathogens, it was found that 13
isolates grown in high nutrient broth (TSB) and eight isolates grown in low nutrient growth
condition (SCB) produced active secondary metabolites (Table 7). Only two isolates, both
from Hawaii, produced active secondary metabolites when grown in both high and low
nutrient broth. One of these isolates was a Bacillus sp. whilst the other has not yet been
characterized by 16S-23S rRNA sequencing. The geographic spectrum of activity shows
that of the 23 isolates demonstrating secondary metabolite activity against the ESKAPE
pathogens, 17 were from Hawaii, 6 were from the Gulf of Mexico, and thus far, none from
Antarctica. The isolates from the Gulf of Mexico that produced active secondary
metabolites were: Nitratireductor sp., Brevibacterium sp., and Bacillus altudinis, with one
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isolate not yet characterized by 16S-23S rRNA sequencing. The Hawaiian isolates that
showed secondary metabolite activity were: Bacillus subtilis, Enterococcus faecium,
Streptomyces sp., Bacillus megaterium, Bacillus sp., Bacillus thuringiensis, Streptomyces
alfalfa, Paenibacillus polymyxa, [Brevibacterium] frigoritolerans, Chelativorans sp. and
Fictibacillus arsenicus, with two isolates not yet characterized by 16S-23S rRNA
sequencing. Of the ESKAPE pathogens, E. faecium was inhibited by 22 extracts while S.
aureus was inhibited by twelve of them. Only one isolate from Hawaii, Bacillus altitudinis,
produced secondary metabolites that inhibited four out of the six ESKAPE pathogens: E.
faecium, S. aureus, K. pneumoniae, and E. cloacae. All secondary metabolites were
tested at 200 µg/mL and therefore were recorded to have activity at this concentration or
possibly lower since further experimentation on these extracts were not performed. Only
three extracts were tested at lower concentrations and activity was found: two from
Hawaii, and one from the Gulf of Mexico. The first extract from Hawaiian species Bacillus
thuringiensis, was tested and found to be active against S. aureus between 25 and 50
µg/mL and against E. faecium between 6 and 12 µg/mL. Activity was found with the other
extract from Hawaii [Brevibacterium] frigoritolerans which was tested at 100 µg/mL
against E. faecium. Finally, the extract originating from Gulf of Mexico species
Nitratireductor sp. was tested at 50 µg/mL and activity was found against S. aureus.

Discussion

Collectively, work performed herein identifies several culturable microbes
isolated from marine sediment of which 23 produced bioactive secondary metabolites
against multi-drug resistant pathogens. Of the 258 microbes characterized from three
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distinct geographic locations, only 7% were Actinobacteria. Bull et. al. discusses how
Actinobacteria make up a small proportion of cultural marine microbes (65), and here we
show this to be true in our study as well. Our findings show that Nitratireductor sp. was
the most abundantly cultured genus in the Antarctic and Gulf of Mexico sediment
samples, while Bacillus sp. was the most abundant found in the Hawaiian sediment
samples.
Nitratireductor sp. belongs to the family Phyllobacteriaceae and is a
common environmental bacterium found in soil and marine sediment (66). This genus
has been detected by culture independent studies in hydrothermal vents in the North
Atlantic Ocean as well as other marine locations that underwent metagenomic sediment
studies (67). Nitratireductor sp. has also been isolated through culture dependent studies
from deep sea Indian Ocean sediment (68) and from Xiaman Island, China (69). To our
knowledge, this is the first time Nitratireductor sp. has been isolated and cultured from
sediment samples from either Antarctica or the Gulf of Mexico. Furthermore, secondary
metabolite activity against E. faecium and S. aureus of the Nitratireductor sp. isolate from
the Gulf of Mexico is a novel finding. In the literature, secondary metabolite activity from
Nitratireductor sp. has not been recorded, yet, it has been found that the EPS layer of this
genus has therapeutic uses such as antioxidant activity and antiproliferative activity
against glioblastoma cells (70). Overall, this microorganism requires further research to
understand its full therapeutic potential.
The most abundant microbial genus cultured from the Hawaiian sediment
sample, Bacillus sp., is found ubiquitously in soil and marine sediment (71). Multiple
Bacillus species have been shown to produce bioactive compounds against E. coli, B.
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subtilis and Saccharomyces cerevisiae at MICs between 8 – 128 µg/mL (72). Our findings
show that secondary metabolites from three Bacillus isolates from Hawaii inhibited E.
faecium and S. aureus. While Barsby et. al. discovered a novel AMP from a tropical
marine Bacillus sp. that inhibits VRE and MRSA that was extracted by methanol (73), to
our knowledge, secondary metabolites extracted by ethyl acetate derived from Hawaiian
Bacillus sp. is a novel finding. Marinobacter sp., the second most abundantly found
microorganism cultured from the Hawaiian sediment, has shown antimicrobial activity of
its extracts against B. subtilis, E. coli, and S. aureus when tested by Kirby Bauer method
(74). Other isolates that produced secondary metabolites from the Hawaiian sediment
were from the genera Streptomyces sp., Fictibacillus arsenicus, and Enterococcus
faecium. Along with Bacilli species, Streptomyces sp. has been shown to produce a
plethora of secondary metabolites that have antimicrobial properties, many of which are
already used therapeutically (75). Alternatively, Enterococcus sp., is generally found in
the marine environment due to fecal contamination, rather than as a residing member of
the marine microbiome (76). It has been isolated off the coast of California as well as on
polluted beaches in Brazil (75). To our knowledge, secondary metabolites originating from
Enterococcus sp. inhibiting E. faecium and S. aureus is a novel finding.
Only one isolate, Bacillus sp. from the Gulf of Mexico, produced secondary
metabolites that inhibited K. pneumoniae, E. cloacae, E. faecium, and S. aureus. All the
other isolates were only able to inhibit E. faecium or S. aureus. While other Bacillus sp.
from the Pacific Ocean have been shown to create secondary metabolites such as B.
licheniformis that can inhibit P. aeruginosa and S. aureus (77), the cultivation of extracts
found in this study is novel. Our extraction method used ethyl acetate while the previous
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used methanol for secondary metabolite extraction. In the literature, it was found that
marine microbes coming from different environments affect the secondary metabolite
production (78). The different environmental effects include pH and nutrient availability
which we attempted to replicate with our two types of growth media. High (TSB) and low
(SCB) nutrient broth were used to grow isolates for extraction in this study. Only two
bioactive isolates were able to produce secondary metabolites that could inhibit
pathogens in both media types. All the other isolates were only able to do so with either
high or low nutrients. Our findings support the concept that microbial environment factors
and nutrient availability have a level of regulation on secondary metabolite production
(79).
Future Directions

Although this research exhibits novel findings, there is much exploration
remaining to be done with marine microbes and their bioactive compounds. Here, we
extracted secondary metabolites from monocultures and tested these compounds against
the ESKAPE pathogens. It has been shown that co-culturing bacteria and then examining
secondary metabolite production is another effective way to find bioactive compounds
(80). When Streptomyces sp. and Bacillus sp. were co-cultivated, a novel peptide was
discovered upon extraction (81). Furthermore, continued research of environmental
microbes and their ability to create antimicrobial compounds potent enough to inhibit the
ESKAPE pathogens could be done by co-culturing the ESKAPEs and marine microbes.
Communication or inhibition by metabolite production between the bacterial cells both
separated from the pathogens and in the presence of the pathogens can then be
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compared. Co-culture plates are engineered with a semipermeable membrane that
separates the bacterial cells within the cultures but allows secondary metabolites to pass
through (82). This work may have significant potential to derive novel compounds for
antibacterial therapeutics. To better understand the molecular mechanics driving
secondary metabolite production, deeper sequencing and omics studies are required.
Here, only 16S-23S rRNA genes were sequenced for characterization purposes.
Unfortunately, this is not consistently thorough enough characterization to differentiate
between strains of species. While our bacterial DNA sequences had very high query
cover matches, it has been discussed in the literature that bacterial top hits can have
completely different niches (and therefore metabolomics) in the environment while having
the same 16S rRNA sequences (83). For example, B. anthracis and B. thuringiensis have
<0.5% sequence differences, with their main difference being plasmids coding important
virulence factors. Therefore, while we show few genera that make up the bulk of
characterized microbes found, these could have different niches and metabolomic
properties due to the presence and regulation other genetic material (84). Overall, our
findings provide a framework and pipeline for studying marine microbes and their ability
to inhibit ESKAPE pathogen growth. Due to the rise in antibiotic resistant pathogens and
the decline in antibiotic research a rapidly emerging need for new pharmacologically
active organic compounds exists. Fortunately, there is a world (and oceans) that have
highly understudied potential to meet this crisis faced today.
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Table 4: Isolates Characterized from Antarctica Sediment and Relative Abundance
of Each Organism. The genera/species shown had the highest percentage identity of
16S-23S rRNA sequenced regions when analyzed using BLASTn.
Genus/Species Identified
Actinobacterium
Agrococcus carbonis

Number of Isolates
Cultured
2
1

Agrococcus jenensis

1

Arthrobacter sp.

5

Chelativorans sp.

2

Corynebacterium variabile

1

Dietzia maris

2

Dietzia psychralcaliphila

7

Dietzia sp.

2

Micrococcus sp.

1

Nitratireductor aquibiodomus

1

Nitratireductor basaltis

2

Nitratireductor sp.

16

Rhodococcus sp.

1

Salinibacterium sp.

1

Sporosarcina psychrophila

2

Sporosarcina sp.

1

Sporosarcina ureae

3

Staphylococcus hominis

1
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Table 5: Isolates Characterized from Hawaiian Sediment and Relative Abundance
of Each Organism. The genera/species shown had the highest percentage identity of
16S-23S rRNA sequenced regions when analyzed using BLASTn.
Genus/Species
Identified
[Brevibacterium]

Number of
Isolates Cultured

Genus/Species
Identified

Number of
Isolates Cultured

frigoritolerans

10

Enterococcus faecium

1

Arthrobacter sp.

1

Fictibacillus arsenicus

1

Bacillus altitudinis

3

Lysinibacillus sp.

2

Bacillus
atrophaeus

Marinobacter
1

hydrocarbonoclasticus

1

butanolivorans

1

Marinobacter litoralis

1

Bacillus cereus

3

Marinobacter sp.

17

Bacillus cohnii

1

Nitratireductor sp.

3

5

Oceanobacillus sp.

1

Bacillus

Bacillus
filamentosus

Paenibacillus
Bacillus flexus

1

polyxyma

1

1

Pseudomonas sp.

1

Bacillus
halotolerans
Bacillus
licheniformis

Rummeliibacillus
2

stabekisii

1

2

Solibacillus silvestris

1

Bacillus
megaterium

Sporosarcina
Bacillus mycoides

4

psychrophila

1

1

Sporosarcina sp.

1

Bacillus
paramycoides
Bacillus
pseudomycoides

Staphylococcus
2

hominis
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1

Table 5 (Continued)
Stenotrophomonas
Bacillus pumilus

3

rhizophila

1

Bacillus safensis

3

Streptomyces alfalfa

1

Streptomyces
Bacillus sp.

18

griseorubens

1

Bacillus subtilis

2

Streptomyces sp.

1

3

Terribacillus goriensis

1

Bacillus
thuringiensis
Bacillus
velezensis

Uncultured bacterium
2

gene

Bacillus
wiedmannii

1

Uncultured prokaryote
1

gene

1

Table 6: Isolates Characterized from the Gulf of Mexico Sediment and Relative
Abundance of Each Organism. The genera/species shown had the highest percentage
identity of 16S-23S rRNA sequenced regions when analyzed using BLASTn.
Genus/Species
Identified
[Brevibacterium]

Number of
Isolates Cultured

Genus/Species
Identified
Bacterial sp.

Number of
Isolates Cultured
1

frigoritolerans

3

Arthrobacter sp.

2

Chelativorans sp.

1

Aureimonas sp.

1

Curtobacterium sp.

1

Fictibacillus
Bacillus altitudinis

2

phosphorivorans

2

Halomonas
Bacillus aryabhattai

2

axialensis

6

Halomonas
Bacillus cereus

8

hydrothermalis
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1

Table 6 (Continued)
Bacillus
megaterium

1

Halomonas sp.

3

Bacillus pumilus

1

Halomonas venusta

2

Bacillus safensis

2

Kocuria indica

3

Bacillus sp.

3

Marinobacter sp.

1

Bacillus

Nitratireductor

thuringiensis

1

basaltis

1

Nitratireductor sp.

36

Micrococcus sp.

1

Phyllobacterium

1

Ochrabactrum
pituitosum

1

myrsinacearum

Psychrobacter
cryohalolentis

1

Uncultured

1

Arthrobacter sp.

Uncultured
bacterium

1

1

Staphylococcus
haemolyticus

Rhizobium sp.

1
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Figure 9: Geographic Microbial Diversity of Genera Cultured from Hawaii,
Antarctica, and the Gulf of Mexico. The only three genera that were isolated from all
three locations and cultured in the laboratory were Arthrobacter and Nitratireductor.

Table 7: Antimicrobial Activity of Secondary Metabolites Collected from Marine
Isolates
Isolate
Location
Gulf of
Mexico
402
Gulf of
Mexico
405
Hawaii
413

Genus/Species
Nitratireductor sp.

Extraction
Media
TSB

Organism
Inhibited
E. faecium
S. aureus

Brevibacterium sp.

TSB

E. faecium
S. aureus

≤ 200 µg/mL

Bacillus subtilis

SCB/TSB

E. faecium
S. aureus

≤ 200 µg/mL
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MIC
≤ 200 µg/mL

Table 7 (Continued)
Hawaii
414
Hawaii
415
Gulf of
Mexico
416
Gulf of
Mexico
417
Hawaii
418
Hawaii
419
Gulf of
Mexico
420
Hawaii
421
Hawaii
424
Hawaii
627

Hawaii
432
Hawaii
461
Hawaii
462
Hawaii
483
Hawaii
493

E. faecium
S. aureus
E. faecium
S. aureus
E. faecium
S. aureus

≤ 200 µg/mL

≤ 200 µg/mL

SCB

E. faecium
S. aureus
K. pneumoniae
E. cloacae
E. faecium
S. aureus
E. faecium
S. aureus
E. faecium

Bacillus megaterium

TSB

E. faecium

≤ 200 µg/mL

Bacillus sp.

TSB

E. faecium

≤ 200 µg/mL

Bacillus thuringiensis

SCB

E. faecium
S. aureus

Streptomyces alfalfa

TSB

E. faecium

> 6 and ≤12
µg/mL
> 25 and ≤ 50
µg/mL
≤ 200 µg/mL

-

TSB

E. faecium

≤ 200 µg/mL

-

TSB

E. faecium

≤ 200 µg/mL

Paenibacillus
polymyxa
[Brevibacterium]
frigoritolerans

TSB

E. faecium

≤ 200 µg/mL

TSB

E. faecium

≤ 200 µg/mL

-

SCB/TSB

Enterococcus faecium

SCB

Bacillus altitudinis

SCB

Bacillus altitudinis

SCB

Streptomyces sp.

TSB

-

SCB

-
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≤ 200 µg/mL
≤ 200 µg/mL

≤ 200 µg/mL
≤ 200 µg/mL
≤ 200 µg/mL

Table 7 (Continued)
Hawaii
496
Hawaii
566
Gulf of
Mexico
570
Hawaii
621
Hawaii
631

[Brevibacterium]
frigoritolerans
Chelativorans sp.

TSB

E. faecium

≤ 100 µg/mL

TSB

≤ 200 µg/mL

Nitratireductor sp.

SCB

E. faecium
S. aureus
S. aureus

Fictibacillus arsenicus

SCB

E. faecium

≤ 200 µg/mL

[Brevibacterium]
frigoritolerans

TSB

E. faecium

≤ 200 µg/mL

(-) Represents isolates that are yet to be characterized
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≤ 50 µg/mL
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